Invivyd (NASDAQ:IVVD) Issues Quarterly Earnings Results

Invivyd (NASDAQ:IVVD) issued its quarterly earnings data on Thursday. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.10, Zacks reports. The firm had revenue of $13.80 million for the quarter, compared to the consensus estimate of $13.57 million.

Invivyd Stock Performance

IVVD opened at $0.74 on Friday. The firm’s fifty day moving average is $0.97 and its two-hundred day moving average is $0.87. The firm has a market cap of $88.35 million, a PE ratio of -0.38 and a beta of 0.09. Invivyd has a twelve month low of $0.35 and a twelve month high of $4.74.

Insiders Place Their Bets

In other Invivyd news, Director Terrance Mcguire sold 86,545 shares of the stock in a transaction on Monday, December 30th. The shares were sold at an average price of $0.48, for a total value of $41,541.60. Following the sale, the director now directly owns 3,170,231 shares in the company, valued at approximately $1,521,710.88. This trade represents a 2.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last three months, insiders have sold 246,138 shares of company stock worth $120,902. Company insiders own 17.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Invivyd in a research note on Monday, February 24th. D. Boral Capital reaffirmed a “buy” rating and set a $9.00 price objective on shares of Invivyd in a research note on Thursday. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $7.89.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.